Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review

Figure 2 Direction of reported outcome signals across comparative cohort and controlled studies. Cell colors indicate the reported direction in primary adjusted analyses where available; they do not imply causality. Interpretation depends on comparator choice, exposure definition, adjustment strategy, and underlying maternal metabolic risk. ¹Discontinuation trajectory denotes events after discontinuation. GDM: Gestational diabetes mellitus; GLP-1: Glucagon-like peptide-1; GWG: Gestational weight gain; HDP: Hypertensive disorders of pregnancy; LGA: Large for gestational age; MCM: Major congenital malformation; NICU: Neonatal intensive care unit; NR: Not reported; PCOS: Polycystic ovary syndrome; PE: Preeclampsia; SGA: Small for gestational age.